Spain's PharmaMar opens new business in Austria

25 October 2016

Spanish drugmaker PharmaMar (PHM: MC) has announced the opening of a new affiliate in Austria with the aim of reinforcing the presence of the company within Europe, one of the world's leading oncology markets.

Luis Mora, managing director at PharmaMar´s Oncology business unit, explains: “The opening of this affiliate is part of our growth strategy in certain European countries; this allows us to offer a better attention to our customers through our own teams. From Austria we can operate directly in Eastern European countries such as Poland and the Czech Republic."

PharmaMar’s lead anti-cancer drug is Yondelis (trabectedin) for soft tissue sarcoma, and Aplidin (plitidepsin) in multiple myeloma is still under Phase III development.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK